Lexington Partners L.P. Acquires New Holdings in Medline $MDLN

Lexington Partners L.P. acquired a new stake in shares of Medline (NASDAQ:MDLN) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 134,232 shares of the company’s stock, valued at approximately $5,638,000. Medline accounts for approximately 1.7% of Lexington Partners L.P.’s holdings, making the stock its 3rd biggest holding.

Several other institutional investors also recently bought and sold shares of MDLN. Sound Income Strategies LLC purchased a new position in Medline during the fourth quarter valued at approximately $25,000. Entrust Financial LLC purchased a new position in Medline in the fourth quarter worth $26,000. NBC Securities Inc. purchased a new position in Medline in the fourth quarter worth $28,000. Global Retirement Partners LLC purchased a new position in Medline in the fourth quarter worth $31,000. Finally, North Star Investment Management Corp. purchased a new position in Medline in the fourth quarter worth $36,000.

Analyst Ratings Changes

Several equities analysts have issued reports on MDLN shares. Evercore reaffirmed an “outperform” rating and issued a $55.00 price target on shares of Medline in a report on Wednesday, February 25th. Weiss Ratings lowered shares of Medline from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, May 15th. Citigroup cut their price target on shares of Medline from $60.00 to $55.00 and set a “buy” rating on the stock in a report on Thursday, May 7th. BNP Paribas Exane cut their price target on shares of Medline from $49.00 to $40.00 and set a “neutral” rating on the stock in a report on Thursday, May 14th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Medline from $50.00 to $53.00 and gave the stock an “overweight” rating in a research note on Tuesday, March 10th. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Medline currently has a consensus rating of “Moderate Buy” and a consensus price target of $50.54.

Medline Price Performance

NASDAQ:MDLN opened at $34.47 on Thursday. The business’s fifty day moving average is $41.79. Medline has a 12 month low of $32.81 and a 12 month high of $50.88.

Medline (NASDAQ:MDLN) last posted its earnings results on Wednesday, May 6th. The company reported $0.33 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.29 by $0.04. The business had revenue of $7.35 billion for the quarter. Medline’s quarterly revenue was up 10.7% compared to the same quarter last year. On average, equities analysts predict that Medline will post 1.5 EPS for the current year.

About Medline

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.